Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
Pacific Biosciences of California, Inc. reports developments in long-read sequencing systems and genomic-analysis workflows. The company designs, develops, and manufactures sequencing solutions, including HiFi long-read sequencing technology, for research applications such as human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, rare disease research, metagenomics, and reproductive genetics.
Recurring PACB updates include quarterly financial results, Revio system adoption, chemistry and library-preparation workflows, partner integrations for bioinformatics and sample preparation, research consortia using HiFi whole genome data, and governance changes. Company releases also reflect its focus on long-read sequencing following the completed disposition of short-read sequencing assets.
Blank Bio announced a $7.2 million seed financing and a strategic collaboration with PacBio (NASDAQ:PACB) to advance RNA foundation models for precision oncology. Funding will support model development, pharma and diagnostic partnerships, and new long-read bulk RNA-seq datasets from up to 100 tumor samples.
PacBio (NASDAQ:PACB) announced the first major study from the HiFi Solves Sub-fertility Consortium in Asia Pacific, using HiFi long-read whole genome sequencing to investigate unexplained subfertility and recurrent pregnancy loss.
The multicenter study sequenced 84 individuals, finding clinically relevant genomic findings in about one in 10 couples and likely diagnostic variants in 4.8% of individuals, using a federated, cross-border data analysis framework.
PacBio (NASDAQ: PACB) reported Q1 2026 results for the quarter ended March 31, 2026. Revenue was $37.2M with consumables $21.8M and instrument revenue $9.7M. GAAP gross profit was $12.8M and GAAP net loss was $8.3M. Ending cash and investments were $276.0M. Company completed sale of short-read assets for $48.1M, was selected by Basecamp Research for the Trillion Gene Atlas, and provided full-year 2026 revenue guidance of $165M–$175M.
PacBio (NASDAQ: PACB) and Lucid Genomics announced on April 21, 2026 a compatibility collaboration under PacBio's Compatible partner program. The partnership certifies Lucid Genomics' tertiary analysis platform for PacBio HiFi long-read sequencing, enabling validated workflows from alignment and variant calling to clinical interpretation and methylation analysis.
The integration aims to streamline analysis, reduce integration risk, and accelerate time-to-insight for clinical and research labs using PacBio systems.
PacBio (NASDAQ: PACB) will report first quarter 2026 financial results and host a conference call on Thursday, May 7, 2026 at 4:30 p.m. ET (1:30 p.m. PT). The call will be webcast and available on the company's investor website.
Live listen and replay access are provided via the investor site at https://investor.pacificbiosciences.com/, toll-free dial-in 1-888-349-0136, and international dial-in 1-412-317-0459.
PacBio (NASDAQ: PACB) and Covaris announced a joint extraction-to-library workflow enabling HiFi long-read sequencing from FFPE tumor samples, integrating Covaris truXTRAC FFPE extraction with PacBio Kinnex library prep and Revio sequencing.
In studies across brain, kidney and uterine tumors the workflow produced >100 million HiFi reads per sample, mean read lengths of 750–1,500 bp, >11,000 structural variants and ~5 million small variants per sample, with ~60% of variants phased into haplotypes.
PacBio (NASDAQ: PACB) announced that Basecamp Research selected PacBio HiFi sequencing on the Revio system with SPRQ-Nx chemistry to power the Trillion Gene Atlas.
The collaboration will generate approximately 100,000 deeply sequenced samples from over 31 countries across 5 continents, creating the largest high-fidelity metagenomic dataset assembled to date.
PacBio (NASDAQ: PACB) appointed Christopher Gibson, Ph.D., to its Board of Directors on March 5, 2026. Dr. Gibson co-founded and chairs Recursion (NASDAQ: RXRX) and brings experience building AI-driven, high-dimensional biology platforms that integrate automation, sequencing-scale data, and machine learning to accelerate discovery.
This appointment aims to strengthen PacBio’s ability to develop data tools and advanced analytics for HiFi long-read sequencing datasets.
PacBio (NASDAQ: PACB) and DNAstack launched the HiFi Solves Global Consortium to create the first global federated dataset of HiFi whole genome sequencing for rare disease research. The consortium spans nearly 30 institutions across 15 countries and has connected or committed to connect >b>10,000 HiFi whole genomes, enabling cross-border queries while data remain under local control.
The platform, hosted by DNAstack at hifisolves.org, supports secure federated queries, preserves data sovereignty, and leverages HiFi accuracy to improve detection of challenging variants and accelerate diagnoses for rare disease patients.
PacBio (NASDAQ: PACB) management will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference on March 2, 2026 at 2:30 PM ET in Boston.
A live webcast will be available on the company's investor site and a replay will be accessible for at least 30 days, according to PacBio.